乳腺癌分子向治疗的创新方法:干扰各种途径信号传输
1Biomedical Engineering Department, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran.
International journal of molecular and cellular medicine
|March 24, 2025
概括
本研究审查了针对乳腺癌亚型的向疗法,包括激素受体阳性和三阴性. 它强调了新兴的治疗方法和治疗耐药性等挑战,并提供了对新药开发的见解.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌呈现出各种各样的亚型:激素受体阳性 (ER+),HER2阳性和三阴性 (TNBC).
- 目前的向疗法集中在雌激素受体 (ER) 和HER2上,但面临着固有的或获得的耐药性挑战.
- 了解瘤生物学已经确定了PI3K/mTOR,细胞循环调节,热冲击蛋白和表观遗传学等途径的新点.
研究的目的:
- 为不同的乳腺癌亚型提供当前和新兴向治疗方法的全面概述.
- 讨论针对ER+,HER2+和TNBC的向治疗的疗效和局限性.
- 突出乳腺癌研究中正在探索的新型治疗策略和目标.
主要方法:
- 针对乳腺癌的向治疗方法的文献评论.
- 对新型治疗药物的临床试验结果的分析.
- 基于乳腺癌亚型 (ER+,HER2+,TNBC) 的治疗方法的分类.
主要成果:
- 埃弗罗利斯 (mTOR抑制剂) 已批准用于治疗耐芳酶抑制剂的高级ER+乳腺癌.
- 新兴的向疗法在临床实验中显示出各种途径的前景.
- 确立的TNBC向性疗法是有限的,在非BRCA突变TNBC中PARP抑制剂的有效性不确定.
结论:
- 针对性疗法对于管理乳腺癌亚型至关重要,目前正在取得进展.
- 解决治疗耐药性和确定新的点是乳腺癌治疗的关键优先事项.
- 需要进一步的研究来制定有效的有针对性的策略,特别是针对三阴性乳腺癌.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.6K
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
1.7K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
